Compare HQL & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HQL | PACB |
|---|---|---|
| Founded | 1992 | 2000 |
| Country | United States | United States |
| Employees | N/A | 575 |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.8M | 459.0M |
| IPO Year | N/A | 2010 |
| Metric | HQL | PACB |
|---|---|---|
| Price | $15.87 | $1.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $2.20 |
| AVG Volume (30 Days) | 128.7K | ★ 5.9M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | $11.22 |
| Revenue Next Year | N/A | $12.41 |
| P/E Ratio | $20.20 | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $10.55 | $0.85 |
| 52 Week High | $17.80 | $2.73 |
| Indicator | HQL | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 32.38 | 33.19 |
| Support Level | $15.67 | $1.36 |
| Resistance Level | $17.51 | $1.73 |
| Average True Range (ATR) | 0.29 | 0.12 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 10.42 | 5.66 |
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.